GSK (LON:GSK) Releases Quarterly Earnings Results

GSK (LON:GSK) posted its quarterly earnings results on Tuesday. The company reported GBX 54.10 EPS for the quarter, Digital Look Earnings reports. GSK had a return on equity of 35.78% and a net margin of 17.78%.

GSK Trading Up 0.7%

LON GSK opened at GBX 2,044 on Wednesday. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79. GSK has a one year low of GBX 1,288.61 and a one year high of GBX 2,282. The company has a 50-day simple moving average of GBX 1,935.75 and a 200-day simple moving average of GBX 1,990.76. The firm has a market capitalization of £81.87 billion, a PE ratio of 14.38, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Citigroup cut their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,950 target price on shares of GSK in a research report on Monday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Thursday, May 28th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of GBX 2,041.43.

Insider Buying and Selling

In related news, insider Jonathan Symonds bought 1,550 shares of the stock in a transaction dated Friday, June 19th. The stock was bought at an average cost of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Vishal Sikka purchased 1,266 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, for a total transaction of £64,173.54. Insiders have acquired a total of 3,625 shares of company stock worth $13,495,004 over the last quarter. 0.20% of the stock is owned by company insiders.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK raised its margin outlook and announced plans to generate approximately £1.9 billion (about $2.5 billion) in annual savings. The savings are expected to come from mature products, procurement and supply-chain efficiencies, helping fund research and development and accelerate new medicines. GSK Plans Annual Savings of £1.9 Billion to Enable R&D Spend
• Positive Sentiment: Partner Hansoh reported a successful late-stage trial for a bone-cancer therapy licensed by GSK. The result strengthens GSK’s oncology pipeline, although regulatory approval and the eventual commercial contribution remain uncertain. GSK partner Hansoh posts late-stage trial win for bone cancer therapy
• Positive Sentiment: GSK reported quarterly EPS of GBX 54.10, with a 35.78% return on equity and a 17.78% net margin, providing evidence of continued profitability as management reshapes the business.
• Neutral Sentiment: GSK plans to close its historic Stevenage research site and shift research activity to Cambridge. Management says the consolidation should improve drug-development speed, but the transition could create execution and employee-relations risks. GSK to shut historic Stevenage site and switch research centre to Cambridge
• Negative Sentiment: The restructuring involves job reductions and reflects GSK’s preparation for a patent cliff, raising concerns about future revenue pressure as key products lose exclusivity. GSK prepares for patent cliff with $2.5B cost-cutting plan
• Negative Sentiment: Deutsche Bank reaffirmed its “Hold” rating and set a GBX 1,950 price target, below the stock’s recent trading level, signaling limited near-term upside in the bank’s view. Deutsche Bank Reaffirms Hold Rating for GSK

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.